The Predictive Value of Interim and Final [18F] Fluorodeoxyglucose Positron Emission Tomography after Rituximab-Chemotherapy in the Treatment of Non-Hodgkin's Lymphoma: A Meta-Analysis

<table>Forest plot of four included studies in non-DLBCL (F-PET, PFS). Pooled effect (HR) and heterogeneity test of F-PET-positive scan on PFS in non-DLBCL patients (PET: positron emission tomography; PFS: progression-free survival; HR: hazard ratio; DLBCL: diffuse large B-cell lymphoma).</table>

BioMed Research International

fig6

Figure 6

Figure 6: The Predictive Value of Interim and Final [18F] Fluorodeoxyglucose Positron Emission Tomography after Rituximab-Chemotherapy in the Treatment of Non-Hodgkin's Lymphoma: A Meta-Analysis 

Figure 6 | The Predictive Value of Interim and Final [18F] Fluorodeoxyglucose Positron Emission Tomography after Rituximab-Chemotherapy in the Treatment of Non-Hodgkin's Lymphoma: A Meta-Analysis 